Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more
Start a new interaction query Switch to Table View

Generate a personalised report in PDF format

Potential Interaction

Darunavir + ritonavir (DRV/r)

Solifenacin

Quality of Evidence: Very Low

Summary:

Coadministration has not been studied. Solifenacin is metabolized by CYP3A4 and concentrations are likely to increase due to inhibition of CYP3A4. A 3-fold increase in solifenacin exposure was observed with ketoconazole (a strong inhibitor of CYP3A4). It is recommended that solifenacin dosage should be limited to 5 mg once daily if coadministered with a strong CYP3A4 inhibitor such as ritonavir.

Description:

Coadministration has not been studied. Use with caution. Monitor for solifenacin adverse reactions, dose reduction of solifenacin may be necessary.
Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, September 2022.

Coadministration with darunavir/ritonavir may increase solifenacin concentrations. When solifenacin is co-administered with darunavir/ritonavir, do not exceed a solifenacin dose of 5 mg once daily.
Prezista Prescribing Information, Janssen Pharmaceuticals Inc, March 2023.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.